抗TNF治疗类风湿关节炎患者持续缓解与低疾病活动度的预测因素、人口学特征及频率
基于英国风湿病学会生物制剂注册库数据,研究抗TNF治疗的类风湿关节炎患者中持续DAS28缓解和低疾病活动度(LDA)的频率及预测因素,并比较2001-2010年与2010-2013年两个时段的变化。结果显示2144例(14.9%)和3802例(26.3%)患者分别达到持续缓解或LDA,总体比例随时间显著增加,但持续缓解/LDA仍不常见。
要点
- 阿达木单抗(对比依那西普)、更高的患者总体评估、从不吸烟或已戒烟、更高的肿胀关节数、更近开始抗TNF及联用MTX与持续缓解/LDA正相关。
- 基线功能状态差(HAQ)、女性、开始抗TNF时年龄较大、英夫利西单抗(对比依那西普)、BMI增加及基线ESR更高是持续缓解/LDA的负向预测因素。
- 在2010-2013年亚组分析中,联用MTX与持续缓解或LDA的可能性增加无关。
核心结论
- 抗TNF治疗的持续缓解/LDA仍不常见,但达到持续缓解和LDA的总体比例随时间显著增加。
研究设计与样本
- 研究使用英国风湿病学会类风湿关节炎生物制剂注册库数据,按时间分为2001-2010年和2010-2013年两个亚组。
- 持续缓解和LDA定义为DAS28-ESR阈值持续6个月,预测变量基于既往系统综述并以多变量logistic回归建模。
主要发现
- 总体2144例(14.9%)达到持续缓解,3802例(26.3%)达到持续LDA。
- 持续缓解/LDA的正向预测因素包括阿达木单抗(对比依那西普)、更高的患者总体评估、从不吸烟和已戒烟(对比当前吸烟)、更高的肿胀关节数、更近开始抗TNF及联用MTX(2010-2013亚组除外)。
- 持续缓解/LDA的负向预测因素包括基线功能状态差(HAQ)、女性、开始抗TNF时年龄较大、英夫利西单抗(对比依那西普)、BMI增加及基线ESR更高。
- 更高的压痛关节数仅与持续LDA负相关。
- 2010-2013年亚组分析中,联用MTX与持续缓解或LDA的可能性增加无关。
关键数值与推荐
- 持续缓解和LDA依据DAS28-ESR阈值持续6个月定义。
临床怎么用
- 临床中可关注阿达木单抗使用、患者总体评估较高、从不吸烟或已戒烟、肿胀关节数较高、更近开始抗TNF及联用MTX等与持续缓解/LDA正相关的因素。
- 需注意女性、年龄较大、基线功能状态差、BMI增加、基线ESR更高及英夫利西单抗使用与持续缓解/LDA负相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the frequency and predictors of sustained 28-joint DAS (DAS28) remission and low disease activity (LDA) in patients receiving anti-TNF therapy and changes in responses over a 12 year period. METHODS: Data from the British Society for Rheumatology Biologics Registry for Rheumatoid Arthritis were used. Sustained remission and LDA were defined according to DAS28-ESR thresholds sustained for 6 months. The dataset was dichotomized into sequential chronological subgroups (2001-2010 and 2010-2013). Predictive variables were identified from a previous systematic review and modelled using multivariable logistic regression. RESULTS: Overall, 2144 (14.9%) and 3802 (26.3%) patients achieved sustained remission or LDA, respectively. Positive predictors of sustained remission/LDA included adalimumab (vs etanercept), greater patient global assessment, never- and ex-smoker status (vs current smoking), greater swollen joint count, more recent commencement of anti-TNF and MTX co-prescription (except in the 2010-2013 subgroup). Negative predictors of sustained remission and LDA included poor baseline functional status (HAQ), female gender, older age at starting anti-TNF, infliximab use (vs etanercept), increasing BMI and greater baseline ESR. Increasing tender joint count was negatively associated with sustained LDA only. The overall proportion of patients achieving sustained remission and LDA has increased significantly over time. CONCLUSION: Sustained remission/LDA on anti-TNF treatment remains uncommon. Adalimumab use, greater patient global assessment, never- and ex-smoker status, greater swollen joint count, more recent commencement of anti-TNF and MTX co-prescription are associated with achievement of sustained remission/LDA. However, co-prescription of MTX was not associated with an increased likelihood of achieving sustained remission or LDA in the analysis of more recent anti-TNF responses.
引用
- Hamann PDH, Pauling JD, McHugh N, et al. Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. Rheumatology (Oxford). 2019. PMID: 31155669. doi:10.1093/rheumatology/kez188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。